Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to compare the outcomes of upper limb motor therapy conducted by a physiotherapist with robot-assisted therapy using the Luna EMG device in patients in the subacute phase after stroke. Additionally, the study will examine the correlation between changes in muscle tone and motor function improvement. The randomized controlled trial will be conducted at the Rehabilitation Department of the T. Marciniak Lower Silesian Specialist Hospital in Wrocław, Poland. Two groups (robot-assisted vs. conventional therapy) will perform identical sets of movements with matched repetition counts over a 6-week therapy period. Functional improvement will be assessed using Fugl-Meyer Upper Extremity Assessment (FMA-UE), Box and Block Test (B&BT), EQ-5D-5L, and MyotonPro measurements.
Stroke often leads to upper limb motor impairment, spasticity, and reduced independence. Robot-assisted rehabilitation, including devices like Luna EMG, may increase therapy intensity and patient motivation through feedback and movement intention detection via EMG signals.
This interventional study includes 58 participants post-stroke, randomly assigned to either robot-assisted therapy (Luna EMG) or conventional physiotherapist-led therapy. Both groups receive standard rehabilitation (75 minutes/day), with an additional 45-minute targeted upper limb training session. Sessions are conducted 5 days a week for 6 weeks.
Muscle tone will be assessed using the Modified Ashworth Scale and biomechanical parameters (stiffness, oscillation) with MyotonPro. Motor performance will be evaluated using the Fugl-Meyer Assessment (FMA-UE) and the Box and Block Test (B&BT). Quality of life and pain perception will also be measured using the EQ-5D-5L and a numeric rating scale (NRS).
Outcome measures will be collected at baseline, after 3 weeks, after 6 weeks of therapy, and 3 weeks post-intervention to evaluate both immediate and short-term effects of the intervention. This study seeks to identify whether robotic rehabilitation offers measurable advantages over traditional methods in early post-stroke recovery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robot-assisted training (Luna EMG) | Experimental | A robotic rehabilitation device using EMG-triggered movement assistance for upper limb recovery after stroke. |
|
| Therapist-assisted training | Active Comparator | A physiotherapist assists the participant in performing 4 specific upper limb movements (50 repetitions each), matching the robotic training protocol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Luna EMG | Device | Participants receive additional upper limb rehabilitation using the Luna EMG robotic system. Each session includes 4 EMG-triggered exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) motor score (0-66) | The motor subscale of the FMA-UE was used to assess upper limb motor function. Higher scores indicate better motor performance. The motor score was predefined as the primary outcome prior to data analysis. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Measure | Description | Time Frame |
|---|---|---|
| Change in total Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score (0-126) | The total score includes motor, sensory, and joint-related components and provides a comprehensive assessment of upper limb impairment. Higher scores indicate better function. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Denis Moskiewicz, M.Sc. | Department of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wrocław, Poland | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lower Silesian Specialist Hospital T. Marciniak - Emergency Medicine Center | Wroclaw | 54-049 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants are randomly assigned to one of two parallel groups: (1) robot-assisted upper limb rehabilitation using Luna EMG or (2) therapist-assisted upper limb rehabilitation. Both groups also receive the same standard rehabilitation program. Randomization was performed using simple urn-based drawing by an individual independent of the study team. An additional balancing step was applied post-assignment to ensure equal group sizes. Interventions are delivered in parallel over 6 weeks, 5 days per week.
Not provided
Not provided
Only the outcomes assessor is blinded. Functional and quality of life assessments (e.g., FMA-UE, Box and Blocks Test, EQ-5D-5L) are conducted by an independent physiotherapist who is not involved in treatment delivery and remains unaware of the participants' group assignments.
Due to the nature of the intervention, participants are aware of their treatment allocation (robot-assisted vs. therapist-assisted training). Similarly, physiotherapists delivering the robotic or therapist-assisted upper limb training (based on 50 EMG-triggered or assisted repetitions) are necessarily aware of group allocation. However, physiotherapists delivering the standard rehabilitation program (common to both groups) are not informed about group assignment and are considered blinded.
|
| Therapist-assisted upper limb training | Behavioral | Participants receive additional upper limb rehabilitation with a physiotherapist performing assisted movements equivalent to the robotic training protocol. Each session includes 4 assisted exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program. |
|
| Box and Blocks Test (B&BT) |
Measures gross manual dexterity by counting the number of blocks transferred in 60 seconds. Higher scores indicate better manual dexterity. |
| Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| EQ-5D-5L | Quality of life across 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Scores are reported on a scale from 0 to 1, where 0 represents the worst possible health state and 1 represents the best possible health state. Higher scores indicate better quality of life. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Tone - Modified Ashworth Scale (MAS) | Spasticity of upper limb muscles scored 0-4. It scores resistance during passive soft-tissue stretching on a scale from 0 to 4. The scale is as follows: 0 = No increase in muscle tone 1 = Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion 1+ = Slight increase in muscle tone, manifested by a catch followed by minimal resistance throughout the remainder (less than half) of the range of motion 2 = More marked increase in muscle tone through most of the range of motion, but affected part(s) easily moved 3 = Considerable increase in muscle tone, passive movement difficult 4 = Affected part(s) rigid in flexion or extension Higher scores indicate greater spasticity (worse outcome). | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Oscillation Frequency Measured by MyotonPRO | Objective measurement of natural oscillation frequency (Hz) of selected upper limb muscles using the MyotonPRO device. This parameter reflects muscle tone and viscoelastic properties. Higher values indicate increased muscle tone. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Stiffness Measured by MyotonPRO | Objective measurement of muscle stiffness (N/m) in selected upper limb muscles using the MyotonPRO device. Stiffness represents resistance to deformation. Higher values indicate greater muscle rigidity. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Elasticity Measured by MyotonPRO | Measurement of muscle elasticity (logarithmic decrement) in selected upper limb muscles using the MyotonPRO device. Lower values indicate more elastic (less stiff) muscle tissue. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Relaxation Time Measured by MyotonPRO | Measurement of muscle relaxation time (milliseconds) in selected upper limb muscles using the MyotonPRO device. This is the time taken for the muscle to return to its initial state after deformation. Shorter relaxation time suggests better muscle function. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Muscle Creep Measured by MyotonPRO | Assessment of muscle creep (deformation over time under constant load) in selected upper limb muscles using the MyotonPRO device. Higher creep values indicate greater viscoelastic deformation. | Baseline, Week 3, Week 6, and 3 weeks after therapy completion |
| Pain Intensity (NRS 0-10) | Numeric pain rating scale (0 = no pain, 10 = worst imaginable pain). | Baseline, Week 3, Week 6, and 3 weeks after therapy completion (Rest and activity) |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D010291 | Paresis |
| D009128 | Muscle Spasticity |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009122 | Muscle Hypertonia |
| D020879 | Neuromuscular Manifestations |
Not provided
Not provided